Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Approved

Current status date:

2025-07-14

Product name:

XIPERE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02559358

Product Monograph/Veterinary Labelling:

Date: 2025-07-14 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

BAUSCH & LOMB INC
1400 N Goodman Street
Rochester
New York
United States 14609

Class:

Human

Dosage form(s):

Suspension

Route(s) of administration:

Suprachoroidal

Number of active ingredient(s):

1

Schedule(s):

PRESCRIPTION

 

Anatomical Therapeutic Chemical (ATC): See footnote 4

S01BA05 TRIAMCINOLONE

Active ingredient group (AIG) number:See footnote5

0106310006

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
TRIAMCINOLONE ACETONIDE 40 MG / ML
Version 4.1.0

"Page details"

Date modified: